Who are Topical roflumilast's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eucrisa, Eucrisa, Daliresp, Leustatin, Ketas, Diphyllin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/topical-roflumilast.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Topical roflumilast — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical roflumilast (Topical roflumilast) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: phosphodiesterase 4 inhibitor. Area: Dermatology.

phase 3 phosphodiesterase 4 inhibitor phosphodiesterase 4 Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Topical roflumilast (Topical roflumilast) — Arcutis Biotherapeutics, Inc.. Topical roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation in the skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topical roflumilast TARGET	Topical roflumilast	Arcutis Biotherapeutics, Inc.	phase 3	phosphodiesterase 4 inhibitor	phosphodiesterase 4
Eucrisa	Crisaborole	Anacor Pharms Inc	marketed	PDE-4 inhibitor	Phosphodiesterase 4 (PDE-4)	2016-01-01
Eucrisa	CRISABOROLE	Anacor Pharms Inc	marketed	Phosphodiesterase 4 Inhibitor [EPC]	Phosphodiesterase 4	2016-01-01
Daliresp	ROFLUMILAST	Arcutis	marketed	Phosphodiesterase 4 Inhibitor [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	2011-01-01
Leustatin	CLADRIBINE		marketed	Purine Antimetabolite [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1993-01-01
Ketas	IBUDILAST	Kyorin Pharmaceutical	marketed	ibudilast	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1989-01-01
Diphyllin	diprophylline		marketed	diprophylline	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	1951-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-11-23 — Leustatin · 10849919 · Method of Use · US
2041-09-10 — Leustatin · 12533408 · Method of Use · US
2041-09-10 — Leustatin · 12539329 · Method of Use · US

Sponsor landscape (phosphodiesterase 4 inhibitor class)

Arcutis Biotherapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topical roflumilast — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-roflumilast. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing